Latest News and Press Releases

Aberdeen, UK, July 02, 2025 (GLOBE NEWSWIRE) -- As an important hub in the global energy supply chain, Aberdeen is gradually realizing the successful transformation from a traditional energy capital...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Organon To Contact Him Directly To Discuss Their Options If...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023...

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1...

Dublin, July 02, 2025 (GLOBE NEWSWIRE) -- The "Public Safety and Security Market Outlook 2025-2034" report has been added to ResearchAndMarkets.com's offering.Public Safety And Security Market is...

PHILADELPHIA, July 02, 2025 (GLOBE NEWSWIRE) -- A federal securities fraud class action alleging that Virtu Financial Inc. (NYSE: VIRT), and certain of its officers failed to make proper disclosures...

Middlefield Canadian Income PCC Net Asset Value Middlefield Canadian Income PCC Middlefield Canadian Income - GBP PC (a protected cell company incorporated in Jersey with registration number...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To Discuss Their Options If...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options If you...

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer Approval based on pivotal Phase 1/2 LINKER-MM1...